Top

Published in:

01-02-2017 | Research Article

Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial

Authors: K. Kalinsky, T. Zheng, H. Hibshoosh, X. Du, P. Mundi, J. Yang, S. Refice, S. M. Feldman, B. Taback, E. Connolly, K. D. Crew, M. A. Maurer, D. L. Hershman

Published in: Clinical and Translational Oncology | Issue 2/2017

Abstract

Purpose

Reverse Phase Protein Array (RPPA) is a high-throughput antibody-based technique to assess cellular protein activity. The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC).

Methods

In an open-label trial, metformin 1500-mg PO daily was administered prior to resection in 35 non-diabetic patients with stage 0–III BC, body mass index ≥25 kg/m². For RPPA, formalin-fixed paraffin-embedded (FFPE) samples were probed with 160 antibodies. Paired and two-sample t-tests were performed (p ≤ 0.05). Multiple comparisons were adjusted for by fixing the false discovery rate at 25 %. We evaluated whether pre- and post-metformin changes of select markers by RPPA were identified by immunohistochemistry (IHC) in these samples. We also assessed for these changes by western blot in metformin-treated BC cell lines.

Results

After adjusting for multiple comparisons in the 32 tumors from metformin-treated patients vs. 34 untreated historical controls, 11 proteins were significantly different between cases vs. controls: increases in Raptor, C-Raf, Cyclin B1, Cyclin D1, TRFC, and Syk; and reductions in pMAPK^pT202,Y204, JNK^pT183,pT185, Bad^pS112, PKC.alpha^pS657, and Src^pY416. Cyclin D1 change after metformin by IHC was not observed. In cell lines, reductions in JNK^pT183 and Bad^pS112 were seen, with no change in Cyclin D1 or Raptor.

Conclusions

These results suggest that metformin modulates apoptosis/cell cycle, cell signaling, and invasion/motility. These findings should be assessed in larger metformin trials. If confirmed, associations between these changes and BC clinical outcome should be evaluated.

Clinicaltrials.gov identifier

NCT00930579.

Available only for authorised users

Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–8.CrossRefPubMed

Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1013 breast cancer patients with diabetes. Breast Cancer Res Treat. 2013;137(3):807–16. doi:10.1007/s10549-012-2404-y.CrossRefPubMed

Liu B, Fan Z, Edgerton SM, Deng X-S, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.CrossRefPubMed

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302. doi:10.1200/JCO.2009.19.6410.CrossRefPubMedPubMedCentral

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Res. 2006;66(21):10269–73. doi:10.1158/0008-5472.can-06-1500.CrossRefPubMed

Jung J-W, Park S-B, Lee S-J, Seo M-S, Trosko JE, Kang K-S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One. 2011;6(11):e28068. doi:10.1371/journal.pone.0028068.CrossRefPubMedPubMedCentral

Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci. 2013;110(3):972–7. doi:10.1073/pnas.1221055110.CrossRefPubMed

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507–11. doi:10.1158/0008-5472.can-09-2994.CrossRefPubMedPubMedCentral

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–74. doi:10.1172/JCI13505.CrossRefPubMedPubMedCentral

10.

Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest. 2014;32(4):150–7. doi:10.3109/07357907.2014.889706.CrossRefPubMedPubMedCentral

11.

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593–600. doi:10.1200/jco.2011.39.3769.CrossRefPubMed

12.

Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128(3):783–94. doi:10.1007/s10549-011-1612-1.CrossRefPubMed

13.

Niraula S, Dowling RO, Ennis M, Chang M, Done S, Hood N, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821–30. doi:10.1007/s10549-012-2223-1.CrossRefPubMed

14.

Kalinsky K, Hershman DL. Cracking open window of opportunity trials. J Clin Oncol. 2012;30(21):2573–5. doi:10.1200/JCO.2012.42.3293.CrossRefPubMed

15.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):951s–8s.PubMed

16.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167–70.CrossRefPubMed

17.

Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer–a study from the IMPACT trialists. J Clin Oncol. 2005;23(11):2477–92. doi:10.1200/JCO.2005.07.559.CrossRefPubMed

18.

Dowsett M. Optimizing the implementation of future treatment using surrogate end-points. Breast Cancer Res. 2008;10(Suppl 4):S26. doi:10.1186/bcr2186.CrossRefPubMedPubMedCentral

19.

Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512–21. doi:10.1158/1535-7163.MCT-06-0334.CrossRefPubMed

20.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–91. doi:10.1158/0008-5472.CAN-07-6854.CrossRefPubMedPubMedCentral

21.

Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics. 2010;6(4):129–51. doi:10.1007/s12014-010-9055-y.CrossRefPubMedPubMedCentral

22.

Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014;20(14):3870–83. doi:10.1158/1078-0432.CCR-13-1507.CrossRefPubMedPubMedCentral

23.

Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, et al. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci. 2012;10(1):56. doi:10.1186/1477-5956-10-56.CrossRefPubMedPubMedCentral

24.

Quackenbush J. Microarray data normalization and transformation. Nat Genet. 2002;32(Suppl):496–501. doi:10.1038/ng1032ng1032.CrossRefPubMed

25.

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol. 2010;28(16):2784–95. doi:10.1200/jco.2009.25.6529.CrossRefPubMedPubMedCentral

26.

Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. J Clin Oncol. 2011;29(15):e458. doi:10.1200/jco.2011.35.2245.CrossRefPubMed

27.

Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics. 2007;23(15):1986–94. doi:10.1093/bioinformatics/btm283.CrossRefPubMed

28.

Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012;18(8):2269–77. doi:10.1158/1078-0432.CCR-11-2830.CrossRefPubMed

29.

Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909–15.CrossRefPubMed

30.

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D’Aiuto E, Troiani T, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013;19(13):3508–19. doi:10.1158/1078-0432.CCR-12-2777.CrossRefPubMed

31.

Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-kappaB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids. 2014;46(12):2809–22. doi:10.1007/s00726-014-1838-4.CrossRefPubMed

32.

Kim YH, Hwang JH, Kim KS, Noh JR, Choi DH, Kim DK, et al. Metformin ameliorates acetaminophen hepatotoxicity via Gadd45beta-dependent regulation of JNK signaling in mice. J Hepatol. 2015;63(1):75–82. doi:10.1016/j.jhep.2015.02.008.CrossRefPubMed

33.

Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol. 2010;160(5):1195–211. doi:10.1111/j.1476-5381.2010.00762.x.CrossRefPubMedPubMedCentral

34.

Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer. 2013;109(11):2792–7. doi:10.1038/bjc.2013.657.CrossRefPubMedPubMedCentral

35.

Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget. 2015;6(25):21208–24. doi:10.18632/oncotarget.4126.CrossRefPubMedPubMedCentral

36.

Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121(3):492–8. doi:10.1016/j.ygyno.2011.02.021.CrossRefPubMed

37.

Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol. 2012;88(5):1149–56. doi:10.1111/j.1751-1097.2012.01165.x.CrossRefPubMedPubMedCentral

38.

Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011;19(6):275–85.CrossRefPubMed

39.

Brodowska K, Theodoropoulou S, Meyer ZuHorste M, Paschalis E, Takeuchi K, Scott G, et al. Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol. 2014;45(6):2311–24. doi:10.3892/ijo.2014.2650.PubMedPubMedCentral

40.

Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012;11(7):1374–82. doi:10.4161/cc.19798.CrossRefPubMedPubMedCentral

41.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576–86. doi:10.1038/sj.onc.1211024.

42.

Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep. 2013;30(5):2449–57. doi:10.3892/or.2013.2718.PubMed

43.

Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat. 2015;150(1):149–55. doi:10.1007/s10549-015-3307-5.CrossRefPubMed

44.

Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16(8):746–52. doi:10.1007/s12094-013-1144-8.CrossRefPubMed

45.

Arnedos M, Nerurkar A, Osin P, A’Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20(12):1948–52. doi:10.1093/annonc/mdp234.CrossRefPubMed

46.

Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A’Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010;12(5):R76. doi:10.1186/bcr2719.CrossRefPubMedPubMedCentral

Title: Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial
Authors: K. Kalinsky
T. Zheng
H. Hibshoosh
X. Du
P. Mundi
J. Yang
S. Refice
S. M. Feldman
B. Taback
E. Connolly
K. D. Crew
M. A. Maurer
D. L. Hershman
Publication date: 01-02-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 2/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1521-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Clinicaltrials.gov identifier

Please log in to get access to this content

Other articles of this Issue 2/2017

Chronic opioid therapy in long-term cancer survivors

Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Advanced breast cancer clinical nursing curriculum: review and recommendations

FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer